Compare Stocks: CRVS, CELC, RLAY, and ELVN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CELC Celcuity	$88.11 -3.0%	$93.86	$44.42 ▼ $151.02	$4.43B	0.2	1.67 million shs	618,189 shs
CRVS Corvus Pharmaceuticals	$14.73 +7.2%	$13.51	$4.38 ▼ $26.95	$1.16B	0.87	860,882 shs	832,868 shs
ELVN Enliven Therapeutics	$58.78 -1.1%	$49.53	$14.78 ▼ $62.32	$4.35B	0.27	1.00 million shs	1.28 million shs
RLAY Relay Therapeutics	$19.99 +0.3%	$17.91	$3.24 ▼ $20.79	$4.37B	1.69	2.19 million shs	1.98 million shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CELC Celcuity	-2.95%	-4.74%	-18.10%	-29.21%	+88.83%
CRVS Corvus Pharmaceuticals	+7.21%	+5.82%	-6.00%	-7.01%	+237.07%
ELVN Enliven Therapeutics	-1.08%	-3.81%	+15.05%	+34.94%	+224.57%
RLAY Relay Therapeutics	+0.25%	+2.30%	-0.05%	+51.21%	+515.08%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CELC Celcuity	$88.11 -3.0%	$93.86	$44.42 ▼ $151.02	$4.43B	0.2	1.67 million shs	618,189 shs
CRVS Corvus Pharmaceuticals	$14.73 +7.2%	$13.51	$4.38 ▼ $26.95	$1.16B	0.87	860,882 shs	832,868 shs
ELVN Enliven Therapeutics	$58.78 -1.1%	$49.53	$14.78 ▼ $62.32	$4.35B	0.27	1.00 million shs	1.28 million shs
RLAY Relay Therapeutics	$19.99 +0.3%	$17.91	$3.24 ▼ $20.79	$4.37B	1.69	2.19 million shs	1.98 million shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CELC Celcuity	-2.95%	-4.74%	-18.10%	-29.21%	+88.83%
CRVS Corvus Pharmaceuticals	+7.21%	+5.82%	-6.00%	-7.01%	+237.07%
ELVN Enliven Therapeutics	-1.08%	-3.81%	+15.05%	+34.94%	+224.57%
RLAY Relay Therapeutics	+0.25%	+2.30%	-0.05%	+51.21%	+515.08%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CELC Celcuity	2.82	Moderate Buy	$155.18	76.12% Upside
CRVS Corvus Pharmaceuticals	2.88	Moderate Buy	$33.33	126.30% Upside
ELVN Enliven Therapeutics	2.71	Moderate Buy	$72.67	23.62% Upside
RLAY Relay Therapeutics	2.86	Moderate Buy	$25.58	27.98% Upside

Current Analyst Ratings Breakdown

Latest CRVS, CELC, RLAY, and ELVN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/10/2026	RLAY Relay Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
8/10/2026	RLAY Relay Therapeutics	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Market Outperform	$21.00 ➝ $26.00
8/7/2026	RLAY Relay Therapeutics	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$27.00 ➝ $30.00
8/7/2026	RLAY Relay Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/6/2026	ELVN Enliven Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$80.00 ➝ $78.00
8/6/2026	ELVN Enliven Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$80.00 ➝ $82.00
8/6/2026	ELVN Enliven Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$67.00 ➝ $80.00
7/30/2026	CRVS Corvus Pharmaceuticals	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
7/28/2026	CRVS Corvus Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/22/2026	RLAY Relay Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
7/21/2026	RLAY Relay Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$22.00 ➝ $31.00

(Data available from 8/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CELC Celcuity	N/A	N/A	N/A	N/A	$2.17 per share	N/A
CRVS Corvus Pharmaceuticals	N/A	N/A	$0.14 per share	108.40	$2.68 per share	N/A
ELVN Enliven Therapeutics	N/A	N/A	N/A	N/A	$12.22 per share	N/A
RLAY Relay Therapeutics	$10.35M	423.25	N/A	N/A	$3.27 per share	6.11

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CELC Celcuity	-$177.04M	-$3.90	N/A	4,405.50	N/A	N/A	-244.61%	-50.22%	8/13/2026 (Estimated)
CRVS Corvus Pharmaceuticals	-$15.28M	-$0.61	N/A	N/A	N/A	N/A	-36.15%	-33.62%	N/A
ELVN Enliven Therapeutics	-$103.69M	-$1.67	N/A	N/A	N/A	N/A	-18.55%	-18.09%	N/A
RLAY Relay Therapeutics	-$276.48M	-$1.57	N/A	N/A	N/A	N/A	-47.23%	-43.10%	N/A

Latest CRVS, CELC, RLAY, and ELVN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	CELC Celcuity	-$1.16	N/A	N/A	N/A	$4.42 million	N/A
8/6/2026	Q2 2026	CRVS Corvus Pharmaceuticals	-$0.1591	-$0.19	-$0.0309	-$0.19	N/A	N/A
8/6/2026	Q2 2026	RLAY Relay Therapeutics	-$0.3911	-$0.41	-$0.0189	-$0.41	$0.96 million	$0.35 million
8/5/2026	Q2 2026	ELVN Enliven Therapeutics	-$0.3872	-$0.49	-$0.1028	-$0.49	N/A	N/A
5/14/2026	Q1 2026	CELC Celcuity	-$1.07	-$0.97	+$0.10	-$0.97	$2.94 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CELC Celcuity	N/A	N/A	N/A	N/A	N/A
CRVS Corvus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ELVN Enliven Therapeutics	N/A	N/A	N/A	N/A	N/A
RLAY Relay Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CELC Celcuity	6.04	12.31	12.31
CRVS Corvus Pharmaceuticals	N/A	16.16	16.16
ELVN Enliven Therapeutics	N/A	64.07	64.07
RLAY Relay Therapeutics	N/A	22.13	22.13

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CELC Celcuity	63.33%
CRVS Corvus Pharmaceuticals	46.64%
ELVN Enliven Therapeutics	95.08%
RLAY Relay Therapeutics	96.98%

Insider Ownership

Company	Insider Ownership
CELC Celcuity	13.33%
CRVS Corvus Pharmaceuticals	19.70%
ELVN Enliven Therapeutics	3.00%
RLAY Relay Therapeutics	5.04%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CELC Celcuity	40	48.77 million	42.27 million	Optionable
CRVS Corvus Pharmaceuticals	30	84.12 million	67.52 million	Optionable
ELVN Enliven Therapeutics	50	73.27 million	71.07 million	Optionable
RLAY Relay Therapeutics	330	219.14 million	208.10 million	Optionable

CRVS, CELC, RLAY, and ELVN Headlines

Recent News About These Companies

Citizens Jmp Forecasts Strong Price Appreciation for Relay Therapeutics (NASDAQ:RLAY) Stock

August 12 at 2:24 AM | americanbankingnews.com

Citizens Jmp Increases Relay Therapeutics (NASDAQ:RLAY) Price Target to $26.00

August 10 at 9:17 AM | marketbeat.com

Relay Therapeutics, Inc. (NASDAQ:RLAY) Given Consensus Recommendation of "Moderate Buy" by Brokerages

August 9 at 2:28 AM | americanbankingnews.com

Relay Therapeutics, Inc. (NASDAQ:RLAY) Receives Consensus Rating of "Moderate Buy" from Brokerages

August 9 at 2:28 AM | marketbeat.com

Relay Therapeutics (NASDAQ:RLAY) Posts Quarterly Earnings Results, Misses Estimates By $0.02 EPS

August 8, 2026 | marketbeat.com

Relay Therapeutics, Inc. (RLAY) Reports Q2 Loss, Lags Revenue Estimates

August 6, 2026 | zacks.com

Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates

August 6, 2026 | globenewswire.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: Relay Therapeutics (RLAY) and Keros Therapeutics (KROS)

August 6, 2026 | theglobeandmail.com

Dimensional Fund Advisors LP Buys 460,186 Shares of Relay Therapeutics, Inc. $RLAY

August 5, 2026 | marketbeat.com

Arrowstreet Capital Limited Partnership Buys New Shares in Relay Therapeutics, Inc. $RLAY

August 3, 2026 | marketbeat.com

Seven Fleet Capital Management LP Raises Stake in Relay Therapeutics, Inc. $RLAY

August 2, 2026 | marketbeat.com

Perceptive Advisors LLC Boosts Holdings in Relay Therapeutics, Inc. $RLAY

August 2, 2026 | marketbeat.com

Relay Therapeutics (NASDAQ:RLAY) Insider Peter Rahmer Sells 748 Shares of Stock

July 31, 2026 | insidertrades.com

Relay Therapeutics (NASDAQ:RLAY) Insider Sells $13,920.28 in Stock

July 30, 2026 | marketbeat.com

Relay Therapeutics (NASDAQ:RLAY) CFO Sells 1,459 Shares

July 30, 2026 | marketbeat.com

Relay Therapeutics (NASDAQ:RLAY) Insider Donald Bergstrom Sells 2,237 Shares

July 30, 2026 | marketbeat.com

Relay Therapeutics to Announce Second Quarter 2026 Financial Results and Corporate Highlights on August 6, 2026

July 30, 2026 | globenewswire.com

Relay Therapeutics: Revitalized By Breast Cancer Program, But Competition Is Intense

July 30, 2026 | seekingalpha.com

Relay Therapeutics, Inc. (RLAY) Expected to Beat Earnings Estimates: Should You Buy?

July 30, 2026 | zacks.com

Relay Therapeutics (RLAY) Projected to Post Earnings on Thursday

July 30, 2026 | marketbeat.com

Eversept Partners LP Has $2.69 Million Stock Holdings in Relay Therapeutics, Inc. $RLAY

July 28, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRVS, CELC, RLAY, and ELVN Company Descriptions

Celcuity NASDAQ:CELC

$88.11 -2.68 (-2.95%)

Closing price 08/11/2026 04:00 PM Eastern

Extended Trading

$89.36 +1.25 (+1.42%)

As of 09:25 AM Eastern

Celcuity Inc., a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, advanced or metastatic breast cancer, and metastatic castration resistant prostate cancer. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. The company was founded in 2011 and is headquartered in Minneapolis, Minnesota.

Corvus Pharmaceuticals NASDAQ:CRVS

$14.73 +0.99 (+7.21%)

Closing price 08/11/2026 04:00 PM Eastern

Extended Trading

$14.94 +0.21 (+1.43%)

As of 09:26 AM Eastern

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.

Enliven Therapeutics NASDAQ:ELVN

$58.78 -0.64 (-1.08%)

Closing price 08/11/2026 04:00 PM Eastern

Extended Trading

$58.57 -0.21 (-0.36%)

As of 09:23 AM Eastern

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.

Relay Therapeutics NASDAQ:RLAY

$19.99 +0.05 (+0.25%)

Closing price 08/11/2026 04:00 PM Eastern

Extended Trading

$20.14 +0.16 (+0.78%)

As of 09:25 AM Eastern

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CRVS, CELC, RLAY, and ELVN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CRVS, CELC, RLAY, and ELVN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CRVS, CELC, RLAY, and ELVN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRVS, CELC, RLAY, and ELVN Company Descriptions

Celcuity NASDAQ:CELC

Corvus Pharmaceuticals NASDAQ:CRVS

Enliven Therapeutics NASDAQ:ELVN

Relay Therapeutics NASDAQ:RLAY

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CRVS, CELC, RLAY, and ELVN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CRVS, CELC, RLAY, and ELVN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CRVS, CELC, RLAY, and ELVN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRVS, CELC, RLAY, and ELVN Company Descriptions

Celcuity NASDAQ:CELC

Corvus Pharmaceuticals NASDAQ:CRVS

Enliven Therapeutics NASDAQ:ELVN

Relay Therapeutics NASDAQ:RLAY

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools